WEE1 and small cell lung carcinoma: This kinase has become a target of interest in SCLC, and the first-in-class WEE1 inhibitor adavosertib (AZD1775) has demonstrated a good safety and tolerability profile in a phase 1 study conducted in patients with advanced solid tumors including SCLC [95].